What dose and OAR constraints you use for boost with IMRT or SBRT when a patient with cancer of the cervix is not candidate for brachytherapy?
Could you discuss how you decide between IMRT or SBRT boost for a patient who is not able to receive intracavitary or interstitial HDR or LDR brachytherapy?
Answer from: Radiation Oncologist at Academic Institution
Concurrent chemoradiotherapy plus brachytherapy boost (intracavitary or interstitial) is the standard of care in patients with locally advanced cervical cancer. In light of published data suggesting inferior survival if brachytherapy is omitted from definitive treatment, we do not recommend utilizin...
Comments
Radiation Oncologist at Loyola University Chicago Stritch School of Medicine Thanks to Bob for the answer. In 25 years of pract...
Radiation Oncologist at Affiliated Oncologists Hear Hear.
Radiation Oncologist at Washington University School of Medicine Agree strongly
Radiation Oncologist at Harbin Clinic Cancer Center Agree
Thanks to Bob for the answer. In 25 years of pract...
Hear Hear.
Agree strongly
Agree